The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene
Published version of a preprint
Abstract
Loss-of-function mutations in the retinoblastoma gene RB1 are common in several treatment-refractory cancers such as small-cell lung cancer and triple-negative breast cancer. To identify drugs synthetic lethal with RB1 mutation (RB1mut), we tested 36 cell-cycle inhibitors using a cancer cell panel profiling approach optimized to discern cytotoxic from cytostatic effects. Inhibitors of the Aurora kinases AURKA and AURKB showed the strongest RB1 association in this assay. LY3295668, an AURKA inhibitor with over 1,000-fold selectivity versus AURKB, is distinguished by minimal toxicity to bone marrow cells at concentrations active against RB1mut cancer cells and leads to durable regression of RB1mut tumor xenografts at exposures that are well tolerated in rodents. Genetic suppression screens identified enforcers of the spindle-assembly checkpoint (SAC) as essential for LY3295668 cytotoxicity in RB1-deficient cancers and suggest a model in which a primed SAC creates a unique dependency on AURKA for mitotic exit and survival. Significance: The identification of a synthetic lethal interaction between RB1 and AURKA inhibition, and the discovery of a drug that can be dosed continuously to achieve uninterrupted inhibition of AURKA kinase activity without myelosuppression, suggest a new approach for the treatment of RB1-deficient malignancies, including patients progressing on CDK4/6 inhibitors. See related commentary by Dick and Li, p. 169. This article is highlighted in the In This Issue feature, p. 151
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Identification and characterization of essential genes in the human genome
Wang, T., Birsoy, K., Hughes, N. W., Krupczak, K. M., Post, Y., Wei, J. J., Lander, E. S., & Sabatini, D. M. (2015) · Science · doi:10.1126/science.aac7041 · Cited by 1,617
O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
Gene essentiality and synthetic lethality in haploid human cells
Blomen, V. A., Májek, P., Jae, L. T., Bigenzahn, J. W., Nieuwenhuis, J., Staring, J., Sacco, R., van Diemen, F. R., Olk, N., Stukalov, A., et al. (2015) · Science · doi:10.1126/science.aac7557 · Cited by 857
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Niederst, M. J., Sequist, L. V., Poirier, J. T., Mermel, C. H., Lockerman, E. L., Garcia, A. R., Katayama, R., Costa, C., Ross, K. N., Moran, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms7377 · Cited by 647
Hernando, E., Nahlé, Z., Juan, G., Diaz-Rodriguez, E., Alaminos, M., Hemann, M., Michel, L., Mittal, V., Gerald, W., Benezra, R., et al. (2004) · Nature · doi:10.1038/nature02820 · Cited by 562
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.035 · Cited by 430
Research works printed but not linked: 41
- Weinstein, 2002, Cancer. Addiction to oncogenes–the Achilles heal of cancer, Science, 297, 63, 10.1126/science.1073096 · DOI · Paper page
- Kaelin, 2005, The concept of synthetic lethality in the context of anticancer therapy, Nat Rev Cancer, 5, 689, 10.1038/nrc1691 · DOI · Paper page
- Lord, 2015, Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors, Annu Rev Med, 66, 455, 10.1146/annurev-med-050913-022545 · DOI · Paper page
- Tsherniak, 2017, Defining a cancer dependency map, Cell, 170, 564, 10.1016/j.cell.2017.06.010 · DOI · Paper page
- Weiss, 2007, Recognizing and exploiting differences between RNAi and small-molecule inhibitors, Nat Chem Biol, 3, 739, 10.1038/nchembio1207-739 · DOI · Paper page
- Musgrove, 2009, Biological determinants of endocrine resistance in breast cancer, Nat Rev Cancer, 9, 631, 10.1038/nrc2713 · DOI · Paper page
- Condorelli, 2018, Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer, Ann Oncol, 29, 640, 10.1093/annonc/mdx784 · DOI · Paper page
- Manning, 2012, RB: mitotic implications of a tumour suppressor, Nat Rev Cancer, 12, 220, 10.1038/nrc3216 · DOI
- Malumbres, 2011, Oncogene-induced mitotic stress: p53 and pRb get mad too, Cancer Cell, 19, 691, 10.1016/j.ccr.2011.05.023 · DOI
- Herrera-Abreu, 2016, Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer, Cancer Res, 76, 2301, 10.1158/0008-5472.CAN-15-0728 · DOI · Paper page
- Dean, 2010, Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure, Oncogene, 29, 4018, 10.1038/onc.2010.154 · DOI · Paper page
- Zhao, 2014, Mutation of the retinoblastoma tumor suppressor gene sensitizes cancers to mitotic inhibitor induced cell death, Am J Cancer Res, 4, 42
- Peng, 2015, Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers, Cancer Cell, 28, 384, 10.1016/j.ccell.2015.08.002 · DOI · Paper page
- Robinson, 2013, RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs, PLoS One, 8, e78641, 10.1371/journal.pone.0078641 · DOI
- Gong, 2017, Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib, Cancer Cell, 32, 761, 10.1016/j.ccell.2017.11.006 · DOI · Paper page
- Fallahi-Sichani, 2013, Metrics other than potency reveal systematic variation in responses to cancer drugs, Nat Chem Biol, 9, 708, 10.1038/nchembio.1337 · DOI · Paper page
- Hart, 2015, High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities, Cell, 163, 1515, 10.1016/j.cell.2015.11.015 · DOI · Paper page
- Meyers, 2017, Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells, Nat Genet, 49, 1779, 10.1038/ng.3984 · DOI · Paper page
- Dees, 2012, Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations, Clin Cancer Res, 18, 4775, 10.1158/1078-0432.CCR-12-0589 · DOI
- Boss, 2011, Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors, Ann Oncol, 22, 431, 10.1093/annonc/mdq344 · doi:10.1093/annonc/mdq344
- Schoffski, 2015, Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study, Ann Oncol, 26, 598, 10.1093/annonc/mdu566 · DOI
- Amin, 2016, A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors, Invest New Drugs, 34, 84, 10.1007/s10637-015-0306-7 · DOI
- Macarulla, 2010, Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics, Mol Cancer Ther, 9, 2844, 10.1158/1535-7163.MCT-10-0299 · DOI
- de Groot, 2015, A Cell Biologist's Field Guide to Aurora Kinase Inhibitors, Front Oncol, 5, 285, 10.3389/fonc.2015.00285 · DOI
- Bretones, 2015, Myc and cell cycle control, Biochim Biophys Acta, 1849, 506, 10.1016/j.bbagrm.2014.03.013 · DOI · Paper page
- Brockmann, 2013, Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma, Cancer Cell, 24, 75, 10.1016/j.ccr.2013.05.005 · DOI · Paper page
- Mollaoglu, 2017, MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition, Cancer Cell, 31, 270, 10.1016/j.ccell.2016.12.005 · DOI · Paper page
- Hook, 2012, An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735, Mol Cancer Ther, 11, 710, 10.1158/1535-7163.MCT-11-0184 · DOI
- Zhang, 2012, A novel retinoblastoma therapy from genomic and epigenetic analyses, Nature, 481, 329, 10.1038/nature10733 · DOI · Paper page
- Pessina, 2003, Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics, Toxicol Sci, 75, 355, 10.1093/toxsci/kfg188 · DOI
- Sivakumar, 2015, Spatiotemporal regulation of the anaphase-promoting complex in mitosis, Nat Rev Mol Cell Biol, 16, 82, 10.1038/nrm3934 · DOI · Paper page
- Anand, 2003, AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol, Cancer Cell, 3, 51, 10.1016/S1535-6108(02)00235-0 · DOI · Paper page
- Katayama, 2012, Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73, Cancer Cell, 21, 196, 10.1016/j.ccr.2011.12.025 · DOI
- Hoar, 2007, MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy, Mol Cell Biol, 27, 4513, 10.1128/MCB.02364-06 · DOI · Paper page
- Nijman, 2011, Synthetic lethality: general principles, utility and detection using genetic screens in human cells, FEBS Lett, 585, 1, 10.1016/j.febslet.2010.11.024 · DOI · Paper page
- Leung, 2016, Synthetic lethality in lung cancer and translation to clinical therapies, Mol Cancer, 15, 61, 10.1186/s12943-016-0546-y · DOI
- Toya, 2011, A kinase-independent role for Aurora A in the assembly of mitotic spindle microtubules in Caenorhabditis elegans embryos, Nat Cell Biol, 13, 08, 10.1038/ncb2242 · DOI
- Liu, 2015, Redeployment of Myc and E2f1-3 drives Rb-deficient cell cycles, Nat Cell Biol, 17, 1036, 10.1038/ncb3210 · DOI
- Menssen, 2007, c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability, Cell Cycle, 6, 339, 10.4161/cc.6.3.3808 · DOI
- Scharer, 2008, Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells, J Transl Med, 6, 79, 10.1186/1479-5876-6-79 · DOI
- Bischoff, 1999, The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis, Trends Cell Biol, 9, 454, 10.1016/S0962-8924(99)01658-X · DOI · Paper page
Cited by
Small molecules, big impact: 20 years of targeted therapy in oncology
Bedard, P. L., Hyman, D. M., Davids, M. S., & Siu, L. L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30164-1 · Cited by 610
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
Quintanal-Villalonga, Á., Chan, J. M., Yu, H. A., Pe’er, D., Sawyers, C. L., Sen, T., & Rudin, C. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0340-z · Cited by 572
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543
Wander, S. A., Cohen, O., Gong, X., Johnson, G. N., Buendia-Buendia, J. E., Lloyd, M. R., Kim, D., Luo, F., Mao, P., Helvie, K., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1390 · Cited by 429
Self-citationMechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Álvarez-Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 390
Metadata
- Authors
- Gong, X., Du, J., Parsons, S. H., Merzoug, F. F., Webster, Y., Iversen, P. W., Chio, L.-C., Van Horn, R. D., Lin, X., Blosser, W., Han, B., Jin, S., Yao, S., Bian, H., Ficklin, C., Fan, L., Kapoor, A., Antonysamy, S., Mc Nulty, A. M., Froning, K., Manglicmot, D., Pustilnik, A., Weichert, K., Wasserman, S. R., Dowless, M., Marugán, C., Baquero, C., Lallena, M. J., Eastman, S. W., Hui, Y.-H., Dieter, M. Z., Doman, T., Chu, S., Qian, H.-R., Ye, X. S., Barda, D. A., Plowman, G. D., Reinhard, C., Campbell, R. M., Henry, J. R., & Buchanan, S. G.
- Venue
- Cancer Discovery
- Published
- 2019-02-01
- Volume
- 9
- Issue
- 2
- Pages
- 248-263
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4240150408
- Cited by
- 235
- References
- 12
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- DOE Office of Science by Argonne National Laboratory (DE-AC02-06CH11357)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene. https://app.cochat.ai/papers/10.1158/2159-8290.cd-18-0469
- The paper
- Gong, X., Du, J., Parsons, S. H., Merzoug, F. F., Webster, Y., Iversen, P. W., Chio, L.-C., Van Horn, R. D., Lin, X., Blosser, W., Han, B., Jin, S., Yao, S., Bian, H., Ficklin, C., Fan, L., Kapoor, A., Antonysamy, S., Mc Nulty, A. M., . . . Buchanan, S. G. (2019). Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-18-0469
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.